OncoCyte Corp (OCX) PT Lowered to $0.45 at Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts OCX Hot Sheet
Price: $3.20 --0%
Rating Summary:
4 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Rating Summary:
4 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Join SI Premium – FREE
Needham & Company analyst Mike Matson lowered the price target on OncoCyte Corp (NASDAQ: OCX) to $0.45 (from $1.40) while maintaining a Buy rating.
You May Also Be Interested In
- Aritzia (ATZ:CN) (ATZAF) PT Raised to Cdn$228 at UBS on Strong Growth
- LS Electric Co Ltd (010120:KS) PT Raised to KRW200,000 at Macquarie
- Sherwin-Williams (SHW) PT Lowered to $392 at RBC Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
